FCGR3A and B-cell chronic lymphocytic leukemia: In CLL patients, ibrutinib treatment preserves circulating CD16+ NK cell counts but decreases immature CD16- NK cell counts and reduces the aberrantly elevated NKT cell counts at month 11 and stabilizes it thereafter (Solman et al., 2020, 2021).